Synergy CHC Corp. Income (Loss) from Continuing Operations before Income Taxes, Domestic
Synergy CHC Corp. (SNYR) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$2.24 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-14.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-05-14
- Synergy CHC Corp. income (loss) from continuing operations before income taxes, domestic for the quarter ending 2026-03-31 was -$2.24M, a 344.43% decline year-over-year.
- Synergy CHC Corp. income (loss) from continuing operations before income taxes, domestic for the quarter ending 2025-03-31 was $916.23K.
- Synergy CHC Corp. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$9.77M, a 411.45% decline from fiscal 2024.
- Synergy CHC Corp. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was $3.14M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 3 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|---|
| 2026-03-31 | -$2.24M 10-Q · filed 2026-05-14 | |
| 2025-12-31 | -$9.77M 10-K · filed 2026-04-01 | |
| 2025-03-31 | $916.23K 10-Q · filed 2026-05-14 | |
| 2024-12-31 | $3.14M 10-K · filed 2026-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Functional Brands Inc. (MEHA) | United States | $0.001B | |
| NATURAL ALTERNATIVES INTERNATIONAL INC (NAII) | United States | $0.011B | -1.16 |
| MANNATECH INC (MTEX) | United States | $0.014B | |
| FITLIFE BRANDS, INC. (FTLF) | United States | $0.087B | 16.59 |
| Niagen Bioscience, Inc. (NAGE) | United States | $0.238B | 15.72 |
| USANA HEALTH SCIENCES INC (USNA) | United States | $0.264B | -17.90 |
| Canopy Growth Corp (CGC) | $0.395B | ||
| Tilray Brands, Inc. (TLRY) | United States | $0.554B | -5.97 |
| Cronos Group Inc. (CRON) | $1.223B | ||
| Definium Therapeutics, Inc. (DFTX) | United States | $4.931B | -17.87 |